Published in J Virol Methods on December 20, 2006
Human immunodeficiency virus type 1 subtype distribution in the worldwide epidemic: pathogenetic and therapeutic implications. J Virol (2007) 2.32
The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic. Antiviral Res (2009) 2.03
Thermodynamically modulated partially double-stranded linear DNA probe design for homogeneous real-time PCR. Nucleic Acids Res (2007) 1.82
Advances in developing HIV-1 viral load assays for resource-limited settings. Biotechnol Adv (2010) 1.65
Evaluation of the Abbott m2000rt RealTime HIV-1 assay with manual sample preparation compared with the ROCHE COBAS AmpliPrep/AMPLICOR HIV-1 MONITOR v1.5 using specimens from East Africa. J Virol Methods (2009) 1.45
Comparison of the RealTime HIV-1, COBAS TaqMan 48 v1.0, Easy Q v1.2, and Versant v3.0 assays for determination of HIV-1 viral loads in a cohort of Canadian patients with diverse HIV subtype infections. J Clin Microbiol (2010) 1.28
Comparison of the Abbott realtime human immunodeficiency virus type 1 (HIV-1) assay to the Cobas AmpliPrep/Cobas TaqMan HIV-1 test: workflow, reliability, and direct costs. J Clin Microbiol (2009) 1.18
Systematic review of the performance of HIV viral load technologies on plasma samples. PLoS One (2014) 1.06
Low-cost assays for monitoring HIV infected individuals in resource-limited settings. Indian J Med Res (2011) 1.02
Evaluation of the Cavidi ExaVir Load assay (version 3) for plasma human immunodeficiency virus type 1 load monitoring. J Clin Microbiol (2009) 0.94
Evaluation of the Abbott investigational use only realtime HIV-1 assay and comparison to the Roche Amplicor HIV-1 monitor test, version 1.5. J Mol Diagn (2009) 0.88
Modification of the Abbott RealTime assay for detection of HIV-1 plasma RNA viral loads less than one copy per milliliter. J Virol Methods (2011) 0.88
Ten years of external quality assessment of human immunodeficiency virus type 1 RNA quantification. J Clin Microbiol (2012) 0.87
Comparative evaluation of the performance of the Abbott RealTime HIV-1 assay for measurement of HIV-1 plasma viral load on genetically diverse samples from Greece. Virol J (2011) 0.83
Single real-time reverse transcription-PCR assay for detection and quantification of genetically diverse HIV-1, SIVcpz, and SIVgor strains. J Clin Microbiol (2012) 0.82
Sequence conservation of the region targeted by the Abbott RealTime HBV viral load assay in clinical specimens. J Clin Microbiol (2013) 0.80
Past, present and future molecular diagnosis and characterization of human immunodeficiency virus infections. Emerg Microbes Infect (2012) 0.77
Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against infection with simian human immunodeficiency virus in macaques given multiple virus challenges. J Infect Dis (2006) 5.24
Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis (2005) 3.52
Care of patients with hepatitis C and HIV co-infection. AIDS (2004) 3.46
The perils of pathogen discovery: origin of a novel parvovirus-like hybrid genome traced to nucleic acid extraction spin columns. J Virol (2013) 3.37
Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med (2005) 3.17
Pegylated IFN-alpha2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. AIDS (2003) 3.14
Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis (2005) 2.73
Faldaprevir and deleobuvir for HCV genotype 1 infection. N Engl J Med (2013) 2.68
Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study. J Infect Dis (2012) 2.43
High prevalence of HIV-1 subtype G and natural polymorphisms at the protease gene among HIV-infected immigrants in Madrid. AIDS (2002) 2.36
Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Ann Intern Med (2013) 2.25
HIV testing in a high-incidence population: is antibody testing alone good enough? Clin Infect Dis (2009) 2.23
Assessment of the ability of a fourth-generation immunoassay for human immunodeficiency virus (HIV) antibody and p24 antigen to detect both acute and recent HIV infections in a high-risk setting. J Clin Microbiol (2009) 2.18
Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a European collaborative study. Clin Infect Dis (2003) 2.11
Opportunistic disease and mortality in patients coinfected with hepatitis B or C virus in the strategic management of antiretroviral therapy (SMART) study. Clin Infect Dis (2008) 2.06
Performance of the Celera Diagnostics ViroSeq HIV-1 Genotyping System for sequence-based analysis of diverse human immunodeficiency virus type 1 strains. J Clin Microbiol (2004) 2.01
A metagenomic analysis of pandemic influenza A (2009 H1N1) infection in patients from North America. PLoS One (2010) 1.99
Natural pregnancies in HIV-serodiscordant couples receiving successful antiretroviral therapy. J Acquir Immune Defic Syndr (2006) 1.96
Rilpivirine: a next-generation non-nucleoside analogue for the treatment of HIV infection. Expert Opin Pharmacother (2012) 1.95
High sensitivity of specific genotypic tools for detection of X4 variants in antiretroviral-experienced patients suitable to be treated with CCR5 antagonists. J Antimicrob Chemother (2010) 1.94
Dried blood spots perform well in viral load monitoring of patients who receive antiretroviral treatment in rural Tanzania. Clin Infect Dis (2009) 1.92
Lack of 'occult' hepatitis B virus infection in HIV-infected patients. AIDS (2002) 1.92
No evidence of murine-like gammaretroviruses in CFS patients previously identified as XMRV-infected. Science (2011) 1.90
Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir Ther (2005) 1.85
Sexual transmission is associated with spontaneous HCV clearance in HIV-infected patients. J Hepatol (2008) 1.84
Thermodynamically modulated partially double-stranded linear DNA probe design for homogeneous real-time PCR. Nucleic Acids Res (2007) 1.82
Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study. Clin Infect Dis (2009) 1.81
Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. AIDS (2009) 1.81
Evaluation of eight different bioinformatics tools to predict viral tropism in different human immunodeficiency virus type 1 subtypes. J Clin Microbiol (2008) 1.81
Use of a multifaceted approach to analyze HIV incidence in a cohort study of women in the United States: HIV Prevention Trials Network 064 Study. J Infect Dis (2012) 1.78
Impact of human immunodeficiency virus type 1 (HIV-1) genetic diversity on performance of four commercial viral load assays: LCx HIV RNA Quantitative, AMPLICOR HIV-1 MONITOR v1.5, VERSANT HIV-1 RNA 3.0, and NucliSens HIV-1 QT. J Clin Microbiol (2005) 1.75
Different degree of immune recovery using antiretroviral regimens with protease inhibitors or non-nucleosides. AIDS (2002) 1.68
Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection. AIDS (2006) 1.68
Correlation between human immunodeficiency virus type 1 (HIV-1) RNA measurements obtained with dried blood spots and those obtained with plasma by use of Nuclisens EasyQ HIV-1 and Abbott RealTime HIV load tests. J Clin Microbiol (2009) 1.67
Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects. Clin Infect Dis (2005) 1.66
Rapid development of subacute myelopathy in three organ transplant recipients after transmission of human T-cell lymphotropic virus type I from a single donor. Transplantation (2003) 1.62
High concordance between HIV-1 drug resistance genotypes generated from plasma and dried blood spots in antiretroviral-experienced patients. AIDS (2007) 1.62
Optimal use of maraviroc in clinical practice. AIDS (2008) 1.60
Tracing the HIV-1 subtype B mobility in Europe: a phylogeographic approach. Retrovirology (2009) 1.58
Characterization of antibodies elicited by XMRV infection and development of immunoassays useful for epidemiologic studies. Retrovirology (2010) 1.57
Failure to confirm XMRV/MLVs in the blood of patients with chronic fatigue syndrome: a multi-laboratory study. Science (2011) 1.56
Effect of dietary intervention on highly active antiretroviral therapy-related dyslipemia. AIDS (2002) 1.55
Switch from ritonavir-boosted to unboosted atazanavir guided by therapeutic drug monitoring. AIDS Res Hum Retroviruses (2008) 1.53
Antiretroviral recommendations may influence the rate of transmission of drug-resistant HIV type 1. Clin Infect Dis (2005) 1.52
Is there evidence for an increase in the death rate from liver-related disease in patients with HIV? AIDS (2005) 1.52
HIV-1 drug resistance genotyping from dried blood spots stored for 1 year at 4 degrees C. J Antimicrob Chemother (2008) 1.52
Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine. AIDS (2005) 1.52
Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia. AIDS (2007) 1.52
Spontaneous hepatitis C virus clearance in HIV patients with chronic hepatitis C bearing IL28B-CC alleles using antiretroviral therapy. AIDS (2014) 1.51
Severe liver disease associated with prolonged exposure to antiretroviral drugs. J Acquir Immune Defic Syndr (2006) 1.49
A RealTime HIV-1 viral load assay for automated quantitation of HIV-1 RNA in genetically diverse group M subtypes A-H, group O and group N samples. J Virol Methods (2007) 1.47
Detection of individuals with acute HIV-1 infection using the ARCHITECT HIV Ag/Ab Combo assay. J Acquir Immune Defic Syndr (2009) 1.46
HIV entry inhibitors: mechanisms of action and resistance pathways. J Antimicrob Chemother (2006) 1.46
The prevalence of diverse HIV-1 strains was stable in Cameroonian blood donors from 1996 to 2004. J Acquir Immune Defic Syndr (2008) 1.46
Suboptimal CD4 gains in HIV-infected patients receiving didanosine plus tenofovir. J Antimicrob Chemother (2006) 1.45
Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome. AIDS (2004) 1.44
Design and validation of new genotypic tools for easy and reliable estimation of HIV tropism before using CCR5 antagonists. J Antimicrob Chemother (2009) 1.43
Impact of frequent natural polymorphisms at the protease gene on the in vitro susceptibility to protease inhibitors in HIV-1 non-B subtypes. J Clin Virol (2004) 1.42
Comparison of HIV-1 RNA measurements obtained by using plasma and dried blood spots in the automated abbott real-time viral load assay. J Clin Microbiol (2011) 1.42
Treatment of chronic hepatitis C virus infection: we must target the virus or liver fibrosis? AIDS (2003) 1.42
HCV-specific T-cell responses in HIV/hepatitis C virus-coinfected patients on highly active antiretroviral therapy are comparable to those observed in hepatitis C virus-monoinfected individuals. J Acquir Immune Defic Syndr (2011) 1.42
Subtype variability, virological response and drug resistance assessed on dried blood spots collected from HIV patients on antiretroviral therapy in Angola. J Antimicrob Chemother (2008) 1.42
Antiretroviral drugs and liver injury. AIDS (2008) 1.40
Estimation of HIV incidence in a large, community-based, randomized clinical trial: NIMH project accept (HIV Prevention Trials Network 043). PLoS One (2013) 1.40
Normalization of liver enzymes in an HIV-hepatitis C virus-co-infected patient after potent antiretroviral therapy. AIDS (2002) 1.39
European recommendations for the clinical use of HIV drug resistance testing: 2011 update. AIDS Rev (2011) 1.38
The impact of transmitted drug resistance on the natural history of HIV infection and response to first-line therapy. AIDS (2006) 1.37
Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C-->T polymorphism at the multidrug resistance gene 1. Clin Infect Dis (2005) 1.33
In-depth investigation of archival and prospectively collected samples reveals no evidence for XMRV infection in prostate cancer. PLoS One (2012) 1.33
Performance of the automated Abbott RealTime HIV-1 assay on a genetically diverse panel of specimens from Brazil. J Virol Methods (2006) 1.33
Susceptibility to protease inhibitors in HIV-2 primary isolates from patients failing antiretroviral therapy. J Antimicrob Chemother (2006) 1.33
Performance of three commercial viral load assays, Versant human immunodeficiency virus type 1 (HIV-1) RNA bDNA v3.0, Cobas AmpliPrep/Cobas TaqMan HIV-1, and NucliSens HIV-1 EasyQ v1.2, testing HIV-1 non-B subtypes and recombinant variants. J Clin Microbiol (2008) 1.32
Performance of the automated Abbott RealTime HIV-1 assay on a genetically diverse panel of specimens from London: comparison to VERSANT HIV-1 RNA 3.0, AMPLICOR HIV-1 MONITOR v1.5, and LCx HIV RNA Quantitative assays. J Virol Methods (2006) 1.30
Systematic review of clinical trials evaluating low doses of stavudine as part of antiretroviral treatment. Expert Opin Pharmacother (2007) 1.30
Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel. AIDS (2002) 1.30